1. Home
  2. ACR vs IPHA Comparison

ACR vs IPHA Comparison

Compare ACR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$23.75

Market Cap

143.3M

Sector

Real Estate

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.85

Market Cap

174.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACR
IPHA
Founded
2005
1999
Country
United States
France
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.3M
174.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ACR
IPHA
Price
$23.75
$1.85
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$24.50
$5.00
AVG Volume (30 Days)
49.9K
22.5K
Earning Date
10-29-2025
09-17-2025
Dividend Yield
N/A
N/A
EPS Growth
14.65
N/A
EPS
0.95
N/A
Revenue
$88,952,000.00
$14,839,695.00
Revenue This Year
$4.05
$22.29
Revenue Next Year
$0.38
$43.90
P/E Ratio
$25.11
N/A
Revenue Growth
14.87
N/A
52 Week Low
$14.94
$1.47
52 Week High
$24.17
$3.51

Technical Indicators

Market Signals
Indicator
ACR
IPHA
Relative Strength Index (RSI) 70.16 42.81
Support Level $22.74 $1.85
Resistance Level $24.17 $1.91
Average True Range (ATR) 0.91 0.07
MACD 0.23 -0.00
Stochastic Oscillator 94.16 11.63

Price Performance

Historical Comparison
ACR
IPHA

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: